Nrf2-mediated protection against 6-hydroxydopamine.

Department of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, WI 53705, USA.
Brain Research (Impact Factor: 2.83). 06/2007; 1144:192-201.
Source: PubMed

ABSTRACT Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by cell loss in the substantia nigra resulting in striatal dopamine depletion. Although the cause of sporadic PD is unknown, oxidative stress is thought to contribute to disease pathogenesis. One mechanism by which cells defend themselves against oxidative stress is through the transcriptional upregulation of cytoprotective genes. Under oxidative stress conditions, the transcription factor NF-E2-related factor (Nrf2) binds to the antioxidant response element (ARE) to induce antioxidant and phase II detoxification enzymes. Here we show that loss of Nrf2-mediated transcription exacerbates vulnerability to the neurotoxin 6-hydroxydopamine (6-OHDA) both in vitro and in vivo. We further demonstrate that activation of the Nrf2-ARE pathway by the known chemical inducer tert-butylhydroquinone can protect against 6-OHDA in vitro. Induction of this pathway by transplantation of astrocytes overexpressing Nrf2 can protect against 6-OHDA-induced damage in the living mouse. This suggests that the Nrf2-ARE pathway is a promising target for therapeutics aimed at reducing or preventing cell death in PD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and purposeNeurodegenerative diseases are a major problem afflicting aging populations; however, there are no effective treatments to stop their progression. Oxidative stress and neuroinflammation are common factors in their pathogenesis. Nrf2 is the master regulator to control oxidative stress and melatonin is an endogenous hormone with antioxidative properties that reduces its levels with aging. We have designed a new compound that combines melatonin with Nrf2 induction properties with the idea of achieving improved neuroprotective properties.Experimental approachCompound ITH12674 is a hybrid of melatonin and sulforaphane designed to exert a dual drug-prodrug mechanism of action. We have obtained the proposed hybrid in a single step; to test its neuroprotective properties we have used different in vitro models of oxidative stress related to neurodegenerative diseases and brain ischemia.Key resultsITH12674 shows an interesting neuroprotective profile, improving that of melatonin and sulforaphane; ITH12674 exhibits (i) concentration-dependent protection in cortical neurons subjected to oxidative stress; (ii) decreased ROS production; (iii) augmentation of glutathione concentrations in cortical neurons; (iv) induction of the Nrf2-ARE transcriptional response in transfected HEK293T cells; (v) protection of organotypic cultures of hippocampal slices subjected to oxygen and glucose deprivation and reoxygenation via induction of HO-1 and free radical reduction.Conclusion The melatonin-sulforaphane hybrid ITH12674 combines the signaling pathways of the parent compounds to improve its neuroprotective properties; this open a new line of research for such hybrid compounds to treat neurodegenerative diseases.
    British Journal of Pharmacology 11/2014; · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Activation of microglial cells and impaired mitochondrial function are common pathological characteristics of many neurological diseases and contribute to increased generation of reactive oxygen species (ROS). It is nowadays accepted that oxidative damage and mitochondrial dysfunction are key hallmarks of classical neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease. To counteract the detrimental effects of ROS and restore the delicate redox balance in the central nervous system (CNS), cells are equipped with an endogenous antioxidant defense mechanism consisting of several antioxidant enzymes. The production of many antioxidant enzymes is regulated at the transcriptional level by the transcription factor nuclear factor E2-related factor 2 (Nrf2). Although evidence is accumulating that activation of the Nrf2 pathway represents a promising therapeutic approach to restore the CNS redox balance by reducing ROS-mediated neuronal damage in experimental models of neurodegenerative disorders, only a few Nrf2-activating compounds have been tested in a clinical setting. We here provide a comprehensive synopsis on the role of ROS in common neurodegenerative disorders and discuss the therapeutic potential of the Nrf2 pathway.
    Archive für Toxikologie 08/2014; · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative diseases share common features, including catastrophic neuronal loss that leads to cognitive or motor dysfunction. Neuronal injury occurs in an inflammatory milieu that is populated by resident and sometimes, infiltrating, immune cells-all of which participate in a complex interplay between secreted inflammatory modulators and activated immune cell surface receptors. The importance of these immunomodulators is highlighted by the number of immune factors that have been associated with increased risk of neurodegeneration in recent genome-wide association studies. One of the more difficult tasks for designing therapeutic strategies for immune modulation against neurodegenerative diseases is teasing apart beneficial from harmful signals. In this regard, learning more about the immune components of these diseases has yielded common themes. These unifying concepts should eventually enable immune-based therapeutics for treatment of Alzheimer's and Parkinson's diseases and amyotrophic lateral sclerosis. Targeted immune modulation should be possible to temper maladaptive factors, enabling beneficial immune responses in the context of neurodegenerative diseases.
    Brain Research 09/2014; · 2.83 Impact Factor


Available from